cyrilzakka/clinical-trials huggingface dataset:
A Trial of Zinc and Micronutrients in Tanzanian Children

A randomized clinical trial of multiple micronutrients, zinc, zinc + micronutrients, or placebo among 2400 children born to HIV-negative Tanzanian mothers.

We propose to study the efficacy of zinc or multiple micronutrient supplementation in reducing the risk of infectious diseases and growth faltering among infants and young children in Tanzania. Infants born to HIV-negative women will be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate and B12), micronutrients plus zinc, or a placebo given daily. Children will be followed at monthly clinic visits from age 6 weeks for 18 months. Data obtained will include socioeconomic status, anthropometric data (weight, length, head circumference, and arm anthropometrics), dietary intake (including breastfeeding duration and frequency), hemoglobin, ferritin, and blood smear for malaria. The primary outcomes will be the incidence of diarrhea and respiratory tract infections. Secondary outcomes will be weight and length gain. A subset of children will be tested for blood concentrations of vitamin A, E, zinc and C-reactive protein. All children will receive a large periodic dose of vitamin A every 6 months as per standard of care in Tanzania.

Eligibility Criteria:
Inclusion Criteria:

* Singleton, live born infants born to HIV- negative women
* Mothers will need to have registered for pre-natal care before 34 weeks gestation
* intend to stay in Dar es Salaam for until delivery and 18 months thereafter.

Exclusion Criteria:

* infants born with multiple congenital abnormalities
How Dose Election Event Will Induce Emotion Change of Emergency Room and Critical Unit

In response to the emergence of injuries and illnesses, the manpower of the acute and critical medical team has the requirements. The election keen is rare to see in recent years. The results of the election event will inevitably bring to the emergency and critical unit nursing staff and on-site counter personnel. Certain emotional changes is noted and this study is to understand the impact of the emotional adjustment of personnel in acute and critical units on their own work, to understand the situation of on-site personnel, and to avoid excessive planning of manpower, which will help hospital manpower deployment

I

In 20181124, the mayor of the county and the 2020 president election, after the election, the mood changes of the nursing staff of the emergency and critical unit and the staff of the on-site counter medical department were filled out with a questionnaire to understand the mood changes of the nursing staff and on-site counter staff in each unit and how to adjust Analysis of the impact on clinical work. Exclude those who complete the questionnaire data incompletely, the statistical method used is to calculate the Cronbach's α and correlation coefficient for the questionnaire sample verification.

Eligibility Criteria:
Inclusion Criteria:

* Nursing Manpower in Emergency and Critical Unit

Exclusion Criteria:

* Incomplete questionnaire filled in
The Role of Diaphragmatic Ultrasound as a Predictor of Extubation From Mechanical Ventilation

Aim: To evaluate real-time ultrasound in the evaluation of diaphragmatic thickening, thickening fraction and or excursion to predict extubation outcomes. The investigators aimed to compare these parameters with other traditional weaning measures.

The diaphragm is an important respiratory muscle and dysfunction is very common in patients receiving mechanical ventilation. Diaphragm fatigue occurs even in patients who successfully pass the Spontaneous Breathing Test (SBT). Interrupting ventilation too early can lead to increased cardiovascular and respiratory pressure (CO2).retention and hypoxemia with up to 25% of patients requiring reinstitution of ventilator support. Unnecessary delays in liberation from mechanical ventilation also can be deleterious. Complications such as ventilator-associated pneumonia and ventilator-induced diaphragm atrophy can be seen with short periods of mechanical ventilation thereby prolonging mechanical ventilation. As SBT monitoring is insensitive to detect early signs of load-capacity imbalance. The evaluation of the diaphragmatic thickening fraction (DTF) may be also helpful to assess diaphragmatic function and its contribution to respiratory workload. Ultrasound can be used to detect the deflection of the diaphragm, which helps to identify patients with diaphragm dysfunction

Eligibility Criteria:
Inclusion Criteria:

* Critically ill patients intubated for more than 48 hours who are ready for weaning with the following criteria.

  1. positive end-expiratory pressure (PEEP) ≤ 5 cm H2O.
  2. Fraction of inspired oxygen (FiO2) \< 0.5.
  3. respiratory rate (RR) \< 30 breaths/min.
  4. rapid shallow breathing index \< 105, PaO2/FiO2 \> 200.
* Age\< 65 years.

Exclusion Criteria:

* Age\<18 years.
* Patient with history of plural effusion, trauma to chest and history of mechanical ventilation for \< 6 months.
* patient with neuromuscular diseases affect diaphragm .
A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer

The investigators tries a new method to delineating the oral cavity, oropharynx, larynx and hypopharynx, and use the head-and-neck region to test whether the method can to create a good IMRT plan, and alleviate the oral radiation injury, reduce the incidence of adverse reactions.

Purpose: To assess the dosimetric effect of new delineation approach for oral cavity, oropharynx, larynx and hypopharynx in intensity-modulated radiotherapy(IMRT) treatment planning for head and neck cancer.

Methods: Twenty head and neck cancer patients were treated by IMRT. Target volumes and several organs at risk were delineated with Corvus6．3 treatment planning system. An investigative IMRT plan was generated based on a standard treatment planning protocol, but used a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx. Plans were exported to treatment planning system for quantitative analysis of dose volume parameters. Variables assessed included: maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (EUD), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (OARs) doses, and dose homogeneity inside the target volumes.

.

Eligibility Criteria:
Inclusion Criteria:

- patients with previously untreated of the head and neck cancer who received definitive IMRT at our institution

Exclusion Criteria:

-
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer

Gemcitabine and anthracycline combination has shown encouraging activity as neoadjuvant chemotherapy in locally advanced breast cancer. An addition of sequential gemcitabine and cisplatin, also a highly active combination in this indication, may result in improvement in pathological response and overall survival. Patients with operable breast cancer will be treated in neoadjuvant setting with gemcitabine plus doxorubicin, followed by gemcitabine plus cisplatin.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of breast carcinoma
* No previous chemotherapy, with bidimensionally measurable locally advanced disease
* Adequate performance status (Karnofsky Performance Status \[KPS\] greater than or equal to 70), bone marrow reserves, hepatic, cardiac and renal functions.

Exclusion Criteria:

* Inflammatory breast cancer
* Pregnancy and Breast-feeding
* Serious concomitant disorder or infection
* Previous cancer within the last 5 years or a second primary malignancy.
Effects of Intensive Training on Reocvery of Fingers Dexterity Following Stroke

The investigators aim to test whether intensive training of finger individuation during the sensitive window of the subacute phases can lead to a clinically-meaningful recovery of dexterous movement in stroke patients.


Eligibility Criteria:
Inclusion Criteria:

* First symptomatic ischemic or hemorrhagic stroke
* Clinically evident upper-limb motor deficit
* Understand the study aim, is able to cooperate with the task for the specified time
* Clinically stable

Exclusion Criteria:

* Other neurological or psychiatric illness which affects upper-limb motor function
* An orthopedic or rheumatologic disease that affects the ability to undergo a robotic hand therapy.
* Sensory problems that prevent the patient from reporting pain during the robotic hand therapy
* Skin breakdown or wounds located in places where the hand contacts the robot.
* Patients with C/I to TMS (history of seizures, the existence of cardiac pacer, VP shunt, spinal stimulator or any other hardware that may malfunction at the presence of strong magnetic fields) will no undergo TMS but may participate in the study
* Participation in another interventional study for upper limb rehabilitation
The Effects of Kinesio Taping on Biomechanical and Clinical Outcomes in Runners With Iliotibial Band Friction Syndrome

The aim of this study is to investigate the efficacy and effectiveness of the application of Kinesio Taping in the short-term management of ITBFS in an exploratory randomized control study in two patient groups, an experimental group receiving Kinesio Taping with tension, and a control group receiving Kinesio Taping with no tension.

To determine the immediate effects of taping on the three-dimensional joint kinematics and moments of the lower limb during running in ITBFS patients, and to determine any differences between the experimental and control groups.

To determine the immediate effects of taping on muscle activity of the gluteus maximus, gluteus medius, tensor fascia lata, vastus medialis, and vastus lateralis in ITBFS patients, and to determine any differences between the experimental and control groups.

To determine if the short-term perceptions of pain, symptoms, ADL function, sport and recreation function, quality of Life, and fear of movement are changed with taping, and to determine any differences between the experimental and control groups.

To determine any perceived changes in the stability of the knee joint, comfort and benefits with taping, and to determine any differences between the experimental and control groups.

To determine if muscle strength, muscle length, and functional movement are changed with taping, and to determine any differences between the experimental and control groups.

To explore the relationship between the clinical and biomechanical outcome measures in ITBFS patients.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 18 to 45 years
* Regularly run a minimum of 10 kilometres a week,
* Current symptoms of ITBFS, assessed using the Noble compression test and Ober's test, and pain at lateral femoral condyle during running

Exclusion Criteria:

* History of taking any analgesic or anti-inflammatory drugs for 72 hours prior to testing.
* Previous surgery to the lower limbs,
* Skin allergy to kinesio tape,
* Signs or symptoms of other knee pathologies including; patellofemoral pain, knee joint osteoarthritis, lateral meniscus injury, common peroneal nerve injury, refer pain from lumbar spine, superior tibiofibular joint sprain, and popliteus or bicep femoris tendinitis.
Differential Mobility Spectrometry (DMS) Based Skin Tumor Analysis

The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an electrosurgical instrument.

Patients recruited in the trial receive standard-of-care basal cell carcinoma tumor excision surgery.

Basal cell carcinoma (BCC) is the most common cancer in Caucasians and the average risk of developing BCC is approximately 30% (1,2). In Finland, BCC is the most common cancer and the incidence of BCC is approximately 49/100 000 in men and 45/100 000 in women (3).

There are several types of BCC (4) of which superficial type can be managed with non-operative treatment. All the other types of BCC (micronodular, nodular, infiltrative) require operative treatment which means surgical removal of the tumor with a few millimeters healthy skin margin (5). The aim of the operative treatment is to remove the tumor entirely so that the healthy skin margins are as sparing as possible and that the functional and cosmetic outcomes are as satisfactory as possible. Margin positiveness leads to one or more reoperations which increase the risk of surgical complications.

Differential mobility spectrometry (DMS) based application called automatic tissue analysis (ATAS) can be utilized to identify tumor cells from healthy tissue. Tissue identification is done by analyzing tissue smoke that is generated by the use of an electrosurgical instrument called diathermy (6,7).

The objective of the trial is to test whether it is possible to identify BCC from normal skin by using ATAS. A 4mm punch biopsy of BCC tumor and a control biopsy of healthy skin will be collected from 30 - 40 patients undergoing BCC tumor excision. The biopsies will be examined in the research laboratory with ATAS to test tissue recognition.

Eligibility Criteria:
Inclusion Criteria:

* Punch biopsy diagnosed basal cell carcinoma.
* Tumor diameter of 1,5 cm or larger.
* Operable patient that is willing to participate in the trial.

Exclusion Criteria:

* Tumor diameter of less than 1,5 cm.
* Patient that is unsuitable to take part in the trial, for example, has a tendency to develop keloids.
* Patient that is unwilling to take part in the trial.
* Patient that is not able to understand given information concerning the trial or to give consent to take part in the trial.
Eeva System Imaging Study

The purpose of this clinical trial is to collect imaging data on embryos followed to blastocyst stage (Day 5-6) for ongoing development and validation of the Eeva System.

The purpose of this clinical trial is to collect imaging data on embryos followed to blastocyst stage (Day 5-6) for ongoing development and validation of the Eeva System.

Primary Objectives Include:

To collect imaging data on embryos followed to blastocyst stage (Day 5-6)

Secondary Objectives Include:

To collect enrollment data: demographics, IVF and pregnancy history To collect Day 3, Day 5 and Day 6 embryo morphology data To collect pregnancy test and outcome data To collect pre-implantation genetic screening (PGS) data (if applicable) To collect Frozen Embryo Transfer (FET) data (if applicable)

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Women undergoing in vitro fertilization treatment using their own eggs
* Fresh or Frozen Blastocyst (Day 5-6) transfer
* At least 5 diploid (2PN) embryos at fertilization check
* Willing to have all 2PN embryos imaged by Eeva
* Willing to comply with study protocol and procedures
* Willing to provide written informed consent

Exclusion Criteria:

* Freeze-all due to ovarian hyperstimulation syndrome (OHSS)
* Use of donor egg / gestational carrier
* Fertilization using surgically removed sperm
* History of cancer
* Assisted Hatching (AH) on Day 3
Methadone Oxytocin Option

The purpose of the study is to examine the effects of intranasal oxytocin administration on social cognition in patients receiving methadone maintenance treatment (MMT), examine the effects of intranasal oxytocin administration on opioid craving and on the subjective effects of methadone, and examine the effects of intranasal oxytocin administration on implicit preferences for drug-related and social stimuli in patients receiving MMT.

Hypothesis 1: Patients will perform better on measures of social cognition (including affect recognition and recognition of sarcasm) after administration of oxytocin compared with placebo.

Hypothesis 2: Patients will demonstrate lower craving for opioids and greater subjective effects of methadone after administration of oxytocin compared with placebo.

Hypothesis 3: Patients will demonstrate increased implicit preferences for social stimuli and decreased implicit preferences for drug related stimuli after administration of oxytocin compared with placebo.


Eligibility Criteria:
Inclusion Criteria for patients:

* Primary diagnosis of opioid dependence according to DSM-IV TR
* Opioid of choice be either heroin or oral opioid analgesics
* Currently be on stable dose of methadone with no dose change in the last 14 days

Inclusion Criteria for healthy volunteers

-No diagnosis of mental disorder according to DSM-IV TR

Exclusion Criteria for patients and healthy volunteers:

* Epilepsy
* Current illicit drug use (within the past one month)
* Current sever depression with suicidal thoughts and/or actions
* Addiction to alcohol or drugs other than opiates, caffeine, or nicotine
* Psychotic illness
* Bipolar disorder
* Brain trauma
* Severe Neuropsychological disorder
* Kidney Disease (i.e., kidney stones, recurrent bladder infections, or known kidney failure)
* Sensitivity to preservatives (in particular E216, E218, and chlorobutanol hemihydrate)
* Nasal obstruction, discharge, or bleeding
* Cardiovascular problems (e.g., heart disease, history of heart attacks), high blood pressure (hypertension)
* Habitually drink large volumes of water
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance therapy.

Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and dexamethasone. if a partial remission response or better is achieved, thalidomide plus prednisone maintenance therapy will be given for no more than two years.

Eligibility Criteria:
Inclusion Criteria:

1. Aged \>=18 years
2. diagnosed with WM
3. Untreated or mild treated without standard regimens,especially untreated with rituximab and/or bortezomib
4. symptom patients
5. with life-expectancy more than 3 months.

Exclusion Criteria:

1. diagnosed with other malignancies outside B-NHL within one year(including active centre neural system lymphoma)
2. Transformed lymphoma
3. liver or renal function lesion unrelated to lymphoma
4. serious complications such as uncontrolled diabetes,gastric ulcer or other serious angiocardiopathy determined by the physician
5. HIV positive or active HBV infection or other uncontrolled systematic infection
6. clinical central nervous dysfunction
7. serious surgery within 30 days
8. pregnancy or baby nursing period or un-contracepted child-bearing period woman;
9. allergy to the trail drugs.
Autophagy Markers in Endometrial Polyps

The aim of this research is to evaluate autophagy markers in patients with endometrial polyps

Endometrial polyp are benign formations that are frequently encountered in gynecology practice and have malignant potential. It may be asymptomatic in the clinic or may present with abnormal uterine bleeding. Although its pathophysiology has not been clearly revealed, there are many studies in the literature about it. However, the autophagy pathway emerges as a subject that has never been evaluated. In this study, the investigators would like to prospectively evaluate Beclin 1, LC3A / B and p62 markers in the autophagy pathway in endometrial polyp tissue samples by immunohistochemistry and reveal their importance.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 35 years of age with a histopathologically confirmed diagnosis of endometrial polyp
* patients over the age of 35 whose histopathologically reported normal endometrial biopsy results.

Exclusion Criteria:

* Are under the age of 35,
* those with cognitive dysfunction,
* diagnosed with any type of cancer
* who are under treatment for cancer,
* diabetes mellitus,
* hypertension,
* endometriosis,
* adenomyosis,
* chronic endometritis,
* have an acute or chronic illness,
* patients who have smoked and used alcohol in the last 10 years
Validation of Objective Measures of Place-Based Physical Activity

Usability of the PALMS system, validity of the PALMS system and added value to an existing cohort study.

Hypothesis: Addition of GPS device and use of PALMS system will allow researchers to better examine place-based interventions.

The Personal Activity Location Measurement System (PALMS) researchers at UCSD have created a web-based processing system for location (GPS) and physical activity (accelerometer) data. We will collect data on a pilot sample of 40 Hispanic persons to a) test the validity of PALMS assessments of transportation modes, and activity in different locations against an objective record of activities derived from images collected by Vicon Revue; b) compare PALMS assessments of transportation modes and activity locations to other self-report measures and interview measures; c) assess the construct validity of PALMS-based activity assessment.

We will be assessing the usability of PALMS in a research staff with no previous experience of using the PALMS system. We will be assessing the added value of using PALMS to examine a place-based intervention in an existing cohort study.

Eligibility Criteria:
Validation Study

Inclusion Criteria:

* Adults (18+ years old)
* Self-identify as Hispanic/Latino(a)
* Have a variety of primary transportation modes
* Have a variety of physical activity levels both occupational and leisure
* Commute different distances to the location

Exclusion Criteria:

* Illness that prevents normal activities
* Inability to ambulate
* Unable to wear the devices for up to 7 days
* Unable to complete two phone interviews in English or Spanish
* Unable to complete a written survey in English or Spanish

Usability Testing:

Research staff members of the SDSU Fe en Accion research study.

Added Value Cohort: Fe en Accion

Inclusion Criteria (Participants of the cohort):

* Attend church weekly
* Age: 18 - 65 years old
* Must live in San Diego County
* Live within 4 miles of their church
* engage in less than 150 minutes of leisure time moderate and vigorous physical activity
* Latina woman
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.


Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal as defined by 6 months of spontaneous amenorrhea with serum FSH levels \>40mlU/ml and estradiol \< than = 25 pg/mL or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy and FSH levels \> 40 mlU/ml and estradiol \< than = 25 pg/mL
* Women reporting at least 50 moderate to severe vasomotor symptoms per week, recorded for seven consecutive days
* Aged 40 to 70 years

Exclusion Criteria:

* No estrogen monotherapy or estrogen/progesterone containing drug products within applicable wash out period prior to screening
* Use of SERMs, clonidine within 4 weeks of screening
* Use of CNS active medication within 1 week of screening
* Use of medications (SSRI; SNRI), herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agent known to possibly be effective for the treatment of vasomotor symptoms, within 4 weeks of screening
* Participation in clinical trial within 30 days
* Significant medical or psychiatric illness within past 12 months